Top

Published in:

01-03-2008 | Original Paper

CV-11974, angiotensin II type I receptor antagonist, reduces the severity of indomethacin-induced rat enteritis

Authors: Toshimitsu Okuda, Norimasa Yoshida, Tomohisa Takagi, Osamu Handa, Satoshi Kokura, Hiroshi Ichikawa, Yuji Naito, Toshikazu Yoshikawa

Published in: Digestive Diseases and Sciences | Issue 3/2008

Abstract

The aim of the present study was to examine the effect of angiotensin II type I receptor antagonist, CV-11974, on indomethacin-induced small intestinal injury in rats. Single administration of indomethacin provoked severe inflammatory lesions in the small intestine. The levels of thiobarbituric acid-reactive substances (TBARS), myeloperoxidase (MPO) activities and cytokine-induced neutrophil chemoattractant-1 (CINC-1) in the intestinal mucosa significantly increased in the indomethacin-treated group compared with the sham group. In addition, the angiotensin II type I receptor was increased in the small intestine after the administration of indomethacin. The development of intestinal lesions in response to indomethacin was prevented by pretreatment with CV-11974 together with significant suppression of the increased level of TBARS, MPO activities and CINC-1. These results indicate that CV-11974 protected against the small intestinal damage elicited by indomethacin, which suggests that angiotensin II/AT1 receptor interaction is involved in the pathogenesis of the intestinal inflammation associated with oxidative stress.

Robert A, Asano T (1977) Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 14:333–341PubMedCrossRef

Fang WF, Broughton A, Jacobson ED (1977) Indomethacin-induced intestinal inflammation. Am J Dig Dis 22:749–760PubMedCrossRef

Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, Delacey G, Gumpel MJ, Levi AJ (1987) Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 93:480–489PubMed

Whittle BJ (1981) Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 80:94–98PubMed

Weissenborn U, Maedge S, Buettner D, Sewing KF (1985) Indometacin-induced gastrointestinal lesions in relation to tissue concentration, food intake and bacterial invasion in the rat. Pharmacology 30:32–39PubMed

Redfern JS, Blair AJ 3rd, Lee E, Feldman M (1987) Gastrointestinal ulcer formation in rabbits immunized with prostaglandin E2. Gastroenterology 93:744–752

Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB (1993) Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 17:641–662PubMedCrossRef

Whittle BJ, Laszlo F, Evans SM, Moncada S (1995) Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. Br J Pharmacol 116:2286–2290PubMed

Basivireddy J, Jacob M, Ramamoorthy P, Pulimood AB, Balasubramanian KA (2003) Indomethacin-induced free radical-mediated changes in the intestinal brush border membranes. Biochem Pharmacol 65(4):683–695PubMedCrossRef

10.

Navar LG., Carmines PK, Huang WC, Mitchell KD (1987) The tubular effects of angiotensin II. Kidney Int Suppl 20:S81–S88PubMed

11.

Dzau VJ, Gibbons GH, Pratt RE (1991) Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 18:II100–II105PubMed

12.

Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J (2001) Role of the renin-angiotensin system in vascular disease: expanding the field. Hypertension 38:1382–1387PubMedCrossRef

13.

Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in culutured vascular smooth muscle cells. Circ Res. 74:1141–1148PubMed

14.

Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 97:1916–1923PubMedCrossRef

15.

Good JM, Nihoyannopoulos P, Ghatei MA, Crossman D, Bloom SR, Clark P, Oakley CM, Cleland JG (1994) Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II. Eur Heart J 15:1634–1640PubMed

16.

Sigurdsson A, Held P, Swedberg K (1993) Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 126:1068–1076PubMedCrossRef

17.

Masuko H, Jin MB, Horiuchi H, Suzuki T, Taniguchi M, Shimamura T, Fukai M, Magata S, Ogata K, Ishikawa H, Fujita M, Nagashima K, Furukawa H, Todo S (2001) Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver. Transplantation 71:1034–1039PubMedCrossRef

18.

Stenman E, Edvinsson L (2004) Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats. Stroke 35:970–974PubMedCrossRef

19.

Timmermans V, Peake PW, Charlesworth JA, Macdonald GJ, Pawlak MA (1990) Angiotensin II receptor regulation in anti-glomerular basement membrane nephritis. Kidney Int 38:518–524PubMedCrossRef

20.

Konstam MA (1995) Role of angiotensin converting enzyme inhibitors in preventing left ventricular remodelling following myocardial infarction. Eur Heart J 16(Suppl K):42–48PubMed

21.

Przyklenk K, Kloner RA (1993) Cardioprotection by ACE-inhibitors in acute myocardial ischemia and infarction. Basic Res Cardiol 88(Suppl 1):139–154PubMed

22.

El Bekay R, Alvarez M, Monteseirin J, Alba G., Chacon P, Vega A, Martin-Nieto J, Jimenez J, Pintado E, Bedoya FJ, Sobrino F (2003) Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood 102:662–671PubMedCrossRef

23.

Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, Garg R (2003) Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 88:4496–4501PubMedCrossRef

24.

Raiden S, Nahmod K, Nahmod V, Semeniuk G., Pereira Y, Alvarez C, Giordano M, Geffner JR (2002) Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J Pharmacol Exp Ther 303:45–51PubMedCrossRef

25.

Burnier M, Brunner HR (2000) Angiotensin II receptor antagonists. Lancet 355:637–645PubMedCrossRef

26.

Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K (1993) Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/−)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 266:114–120PubMed

27.

Araya J, Tsuruma T, Hirata K, Yagihashi A (2002) Watanabe N TCV-116, an angiotensin II type 1 receptor antagonist, reduces hepatic ischemia-reperfusion injury in rats. Transplantation 73:529–534PubMedCrossRef

28.

Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, Schulz R (2004) The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 24:467–474PubMedCrossRef

29.

Groth W, Blume A, Gohlke P, Unger T, Culman J (2003) Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 21:2175–2182PubMedCrossRef

30.

Takagi T, Yoshida N, Isozaki Y, Shimozawa M, Katada K, Manabe H, Hanada O, Kokura S, Ichikawa H, Naito Y, Okanoue T, Yoshikawa T (2006) CV-11974, angiotensin II type I receptor antagonist, protects against ischemia-reperfusion injury of the small intestine in rats. Eur J Pharmacol 535:283–290PubMedCrossRef

31.

Ohkawa H, Ohnishi N, Yagi K (1986) Assay for lipid peroxides for animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358CrossRef

32.

Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275PubMed

33.

Grisham MB, Hernandez LA, Granger DN (1986) Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol 251:G567–574PubMed

34.

Watanabe K, Konishi K, Fujioka M, Kinoshita S, Nakagawa H (1989) The neutrophil chemoattractant produced by the rat kidney epithelioid cell line NRK-52E is a protein related to the KC/gro protein. J Biol Chem 264:19559–19563PubMed

35.

Watanabe K, Suematsu M, Iida M, Takaishi K, Iizuka Y, Suzuki H, Suzuki M, Tsuchiya M, Tsurufuji S (1992) Effect of rat CINC/gro, a member of the interleukin-8 family, on leukocytes in microcirculation of the rat mesentery. Exp Mol Pathol 56:60–69PubMedCrossRef

36.

Estelles R, Lopez-Martin J, Milian L, O’Connor JE, Martinez-Losa M, Cerda-Nicolas M, Anam EM, Ivorra MD, Issekutz AC, Cortijo J, Morcillo EJ, Blazquez MA, Sanz MJ (2003) Effect of two phenanthrene alkaloids on angiotensin II-induced leukocyte-endothelial cell interactions in vivo. Br J Pharmacol 140:1057–1067PubMedCrossRef

37.

Paragh G, Szabo J, Kovacs E, Keresztes T, Karpati I, Balogh Z, Pall D, Foris G (2002) Altered signal pathway in angiotensin II-stimulated neutrophils of patients with hypercholesterolaemia. Cell Signal 14:787–792PubMedCrossRef

38.

Tsuruma T, Yagihashi A, Tarumi K, Hirata K (1998) Anti-rat IL-8 (CINC) monoclonal antibody administration reduces ischemia-reperfusion injury in small intestine. Transplant Proc 30:2644–2645PubMedCrossRef

39.

Yagihashi A, Tsuruma T, Tarumi K, Kameshima T, Yajima T, Yanai Y, Watanabe N, Hirata K (1998) Prevention of small intestinal ischemia-reperfusion injury in rat by anti-cytokine-induced neutrophil chemoattractant monoclonal antibody. J Surg Res 78:92–96PubMedCrossRef

40.

Nabah YN, Mateo T, Estelles R, Mata M, Zagorski J, Sarau H, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ (2004) Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 110:3581–3586PubMedCrossRef

Title: CV-11974, angiotensin II type I receptor antagonist, reduces the severity of indomethacin-induced rat enteritis
Authors: Toshimitsu Okuda
Norimasa Yoshida
Tomohisa Takagi
Osamu Handa
Satoshi Kokura
Hiroshi Ichikawa
Yuji Naito
Toshikazu Yoshikawa
Publication date: 01-03-2008
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 3/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-007-9931-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Nutritional status of infants with neonatal cholestasis

Is Single-Cell Apoptosis Sufficient for the Diagnosis of Graft-Versus-Host Disease in the Colon?

Cost-effectiveness Analysis of Strategies for Diagnosing Celiac Disease

Endoscopic Ultrasound-guided Fine Needle Aspiration of a Malignant Pleural Effusion to Diagnose and Stage Lung Cancer: When Should this Approach be Considered?

Gastric Emptying is Altered with the Presence of Gastritis

Association of Multiple Myeloma and Inflammatory Bowel Diseases

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials